EAGAN, Minn. , Oct. 7, 2024 /PRNewswire/ -- Prime Therapeutics LLC (Prime) today announced new, cost-effective Humira biosimilar solutions, offering clients continued flexibility and choice, along with financial risk mitigation strategies designed to maintain and promote access to biosimilars for millions of Americans.
These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model by offering clients access to biosimilar therapies through a broad network of quality specialty pharmacies. Beginning in 2025, Prime will recommend four manufacturers that offer new biosimilar options for plans, including Organon (Hadlima®), Teva (Simlandi®), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty). Plan options will include retaining Humira® in a parity position to biosimilars, biosimilars first, or biosimilars only strategies.
All solutions offer clients access to four, low list-price biosimilar options, with net costs as low as $500 -600 per 30-day supply. Adding these solutions deliver more options to the market that allow providers, pharmacies and members choice, leading to biosimilar conversion success. Further, Prime's recommended options have robust biosimilar pipelines, demonstrating a long-term investment in success in the market to provide members with stability and access to their necessary therapies.
Prime also supports the efforts of biosimilar manufacturers to provide patient support to keep out-of-pocket costs a.